Leerink Swann Initiates Carbylan Therapeutics With Outperform
Analysts at Leerink Swann initiated coverage on Carbylan Therapeutics Inc (NASDAQ: CBYL) with a Outperform rating.
The target price for Carbylan Therapeutics is set to $16.
Carbylan Therapeutics' shares rose 9.04 percent to $5.91 in pre-market trading.
Latest Ratings for CBYL
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2016 | JMP Securities | Downgrades | Market Outperform | Market Perform |
| Mar 2016 | JMP Securities | Maintains | Market Outperform | |
| Feb 2016 | Leerink Swann | Downgrades | Outperform | Market Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Leerink SwannInitiation Analyst Ratings
